Voyager Therapeutics (VYGR) Assets Average (2015 - 2026)
Voyager Therapeutics recorded quarterly Assets Average of $235.8 million in Q1 2026, down 12.76% quarter-over-quarter from $270.3 million in Q4 2025, and down 36.81% year-over-year from $373.1 million in Q1 2025.
Voyager Therapeutics' Assets Average history runs 12 years deep, the most recent figure standing at $235.8 million for Q1 2026.
- In Q1 2026, Assets Average fell 36.81% year-over-year to $235.8 million; the TTM figure through Mar 2026 stood at $235.8 million (down 36.81% YoY), while the FY2025 annual figure was $322.7 million, down 13.3% from the prior year.
- Assets Average came in at $235.8 million for Q1 2026 at Voyager Therapeutics, down from $270.3 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $452.9 million in Q2 2024 to a low of $170.9 million in Q4 2022.
- A 5-year average of $305.9 million and a median of $305.2 million in 2025 frame the typical range for Assets Average.
- Across the five-year window, Assets Average soared 88.96% in 2023 and slumped 36.81% in 2026, its largest moves.
- Voyager Therapeutics' Assets Average stood at $170.9 million in 2022, then surged by 88.96% to $323.0 million in 2023, then gained by 26.81% to $409.5 million in 2024, then plunged by 34.0% to $270.3 million in 2025, then retreated by 12.76% to $235.8 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $235.8 million, $270.3 million, and $305.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 13.04 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 33.42 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 1.72 Bn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 331.70 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 40.89 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 26.06 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 26.03 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 40.71 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 5.05 Bn |
| 10 | Voyager Therapeutics | 230.25 Mn | 88.77 Mn | - | 235.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 235.80 Mn |
| Dec 31, 2025 | 270.30 Mn |
| Sep 30, 2025 | 305.21 Mn |
| Jun 30, 2025 | 337.67 Mn |
| Mar 31, 2025 | 373.15 Mn |
| Dec 31, 2024 | 409.55 Mn |
| Sep 30, 2024 | 431.13 Mn |
| Jun 30, 2024 | 452.91 Mn |
| Mar 31, 2024 | 410.44 Mn |
| Dec 31, 2023 | 322.97 Mn |
| Sep 30, 2023 | 305.09 Mn |
| Jun 30, 2023 | 325.92 Mn |
| Mar 31, 2023 | 247.83 Mn |
| Dec 31, 2022 | 170.92 Mn |
| Sep 30, 2022 | 185.54 Mn |
| Jun 30, 2022 | 206.39 Mn |
| Mar 31, 2022 | 209.02 Mn |
| Dec 31, 2021 | 189.31 Mn |
| Sep 30, 2021 | 196.75 Mn |
| Jun 30, 2021 | 223.22 Mn |
| Mar 31, 2021 | 249.65 Mn |
| Dec 31, 2020 | 265.67 Mn |
| Sep 30, 2020 | 283.61 Mn |
| Jun 30, 2020 | 310.03 Mn |
| Mar 31, 2020 | 338.69 Mn |
| Dec 31, 2019 | 365.49 Mn |
| Sep 30, 2019 | 382.41 Mn |
| Jun 30, 2019 | 399.97 Mn |
| Mar 31, 2019 | 294.19 Mn |
| Dec 31, 2018 | 187.05 Mn |
| Sep 30, 2018 | 205.86 Mn |
| Jun 30, 2018 | 224.84 Mn |
| Mar 31, 2018 | 209.75 Mn |
| Dec 31, 2017 | 162.70 Mn |
| Sep 30, 2017 | 149.66 Mn |
| Jun 30, 2017 | 166.75 Mn |
| Mar 31, 2017 | 182.33 Mn |
| Dec 31, 2016 | 195.78 Mn |
| Sep 30, 2016 | 205.90 Mn |
| Jun 30, 2016 | 214.90 Mn |
| Mar 31, 2016 | 224.72 Mn |
| Dec 31, 2015 | 197.95 Mn |